Cabaletta Bio Announces Proposed Public Offering of Securities

PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. ('Cabaletta' or the 'Company') (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof) and, in lieu of common stock, to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof). Cabaletta also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock and warrants offered in the public offering. All of the shares, pre-funded warrants and accompanying common stock warrants to be sold in the proposed offering are to be sold by Cabaletta.
Jefferies, TD Cowen and Cantor are acting as joint book-running managers for the proposed offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The offering is expected to close on or about June 12, 2025, subject to customary closing conditions.
The shares of common stock, pre-funded warrants, common stock warrants and shares of common stock issuable upon the exercise of the pre-funded warrants and common stock warrants are being offered by Cabaletta pursuant to a shelf registration statement on Form S-3 (File No. 333-278126), as amended by that certain Post-Effective Amendment No. 1 to Form S-3 (No. 333-278126) and that certain Post-Effective Amendment No. 2 to Form S-3 (No. 333-278126), as filed with the U.S. Securities and Exchange Commission (SEC) on March 31, 2025 and declared effective on March 31, 2025. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and may also be obtained, when available, from: Jefferies LLC by mail at Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@jefferies.com; TD Securities (USA) LLC, by mail at 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (833) 297-2926 or by email at TD.ECM_Prospectus@tdsecurities.com; Cantor Fitzgerald & Co. by mail at Attention: Capital Markets, 110 East 59th Street, New York 10022 or by email at prospectus@cantor.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Cabaletta Bio Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA™ platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Rese-cel is currently being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio's headquarters and labs are located in Philadelphia, PA.
Forward-Looking Statements This press release contains 'forward-looking statements' of Cabaletta Bio within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including without limitation, express or implied statements regarding: Cabaletta's business plans and objectives as a whole; Cabaletta's ability to realize its vision of launching the first curative targeted cell therapy designed specifically for patients with autoimmune diseases; Cabaletta's beliefs and expectations regarding the proposed public offering; uncertainties related to market conditions and statements regarding the timing, size and expected proceeds of the proposed public offering; and the safety, tolerability, efficacy, advancement and success of Cabaletta's clinical programs.
Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties related to completion of the public offering on the anticipated terms, or at all, include, but are not limited to, market conditions and the satisfaction of customary closing conditions related to the public offering. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Cabaletta's actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in Cabaletta's most recent annual report on Form 10-K filed on March 31, 2025 and our subsequent quarterly reports on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Cabaletta's other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement related to the public offering to be filed with the SEC.
Contacts
Anup Marda Chief Financial Officer investors@cabalettabio.com

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Insider

24 minutes ago

• Business Insider

The Week That Was, The Week Ahead: Macro & Markets, June 22, 2025

Everything to Know about Macro and Markets Stocks closed mixed on Friday amid hopes for de-escalation in the Middle East, still clocking in a second straight week in the red. Despite eking out a small increase on the last trading day of the holiday-shortened week, the Dow Jones Industrial Average (DJIA) ended the weekly session down 1.77%, returning to a year-to-date loss. Meanwhile, the S&P 500 (SPX) fell 1.28%, and the tech-heavy Nasdaq-100 (NDX) lost 1.31% for the week, with both benchmarks still in the green for the year. Confident Investing Starts Here: The Trade War and The Real War Stock markets were moved by geopolitical news during the week, with the Federal Reserve's policy meeting adding a significant macro highlight. The week opened positively as fears of all-out Mideast war eased, after which the rally crumbled – and crude resumed its climb – as Tehran threatened escalation and former President Donald Trump demanded 'total surrender.' After Thursday's Juneteenth closure, investors returned on Friday hoping for the best – but stocks lost ground throughout the day on another bout of trade news. The declines were led by semiconductor and chip equipment stocks, which fell after The Wall Street Journal reported that the U.S. plans to cancel the blanket waivers that allow international chip companies like Samsung, SK Hynix , and TSMC to easily send American chipmaking equipment to their factories in China. The possibility of new restrictions hit risk appetite that had just begun recovering on signs that Trump is giving a chance to diplomacy vis-à-vis Tehran, and after Fed Governor Christopher Waller said he sees a rate cut in July, adding that the inflation hit from tariffs is likely to be short-lived. The Rock and The Hard Place Wednesday's Fed interest rate decision brought no surprises, as the central bank kept rates unchanged, noting that uncertainty 'has diminished but remains elevated.' Fed Chair Jerome Powell noted that 'the economy is in a solid position,' and the Fed is well-positioned to provide a timely response to any economic developments. The Fed's 'Dot Plot' also remained unchanged, as policymakers still expect two rate cuts this year. However, expectations for inflation and unemployment by the end of 2025 both rose, while projections for GDP growth declined, underscoring the Fed's difficulties in establishing monetary policy amid contrasting economic crosscurrents and elevated geopolitical risks. Meanwhile, economic data appear to be confirming the Fed's view of a gradually softening economy. Retail sales fell for a second straight month in May, declining by the most so far in 2025 and marking the first back-to-back monthly decline since the end of 2023. Industrial production declined again, and the NAHB homebuilder confidence index slumped to its lowest since the end of 2022 – while new home construction dropped to the lowest level since 2020. This and other data, coupled with the Fed's updated economic projections, might keep 'stagflation' in the headlines. Sunday's news that the U.S. had struck Iran's nuclear facilities set the stage for a further rise in oil prices, adding short-term inflationary pressures and weighing on investor risk appetite. Markets remain wedged between escalating global risk and weakening fundamentals – with Fed policy constrained, volatility high, and few near-term catalysts to shift sentiment decisively. Stocks That Made the News ▣ Chip equipment makers Lam Research (LRCX), KLA Corp (KLAC), and Applied Materials (AMAT) – along with chipmakers including Nvidia (NVDA), Broadcom (AVGO), and TSMC (TSM) – slumped on the report that the Commerce Department is mulling plans to make it more difficult for U.S. semiconductor equipment to be shipped to Chinese fabs. ▣ Accenture (ACN) shares tumbled by more than 9% on the week after it reported weaker-than-expected bookings for its fiscal third quarter. Although the professional services giant beat on sales and profits, which were boosted by demand related to AI services, the earnings call reflected hesitancy regarding the near-term outlook due to the uncertain global economic backdrop. ▣ Kroger (KR) shares surged by nearly 9% on better-than-expected profit and identical sales growth in fiscal Q1. The operator of the largest chain of traditional grocery stores in the U.S. boosted its full-year identical sales growth forecast and maintained its other guidance. ▣ Coinbase Global (COIN) was by far the best S&P 500 performer last week, clocking in over 20% gain. The shares of the largest U.S. cryptocurrency exchange operator soared after the Senate passed the GENIUS Act, providing a regulatory framework for companies issuing stablecoins and introducing guardrails to prevent the collapse of the digital assets. The Q1 2025 earnings season is over, but several notable earnings releases are still scheduled for the next few days. These include Carnival (CCL), FedEx (FDX), TD SYNNEX (SNX), Micron (MU), General Mills (GIS), Paychex (PAYX), and Nike (NKE).

Yahoo

44 minutes ago

• Yahoo

Better Cybersecurity Stock: CrowdStrike or SentinelOne?

CrowdStrike and SentinelOne have similar business models and offerings. CrowdStrike is much larger. SentinelOne trades at a steep discount to CrowdStrike. 10 stocks we like better than CrowdStrike › Artificial intelligence (AI) may have many benefits, but it's also making it easier for hackers, online criminals, and other digital malefactors to threaten businesses, and those threats are getting more potent. Keeping them at bay requires a lot of funds to be devoted to cybersecurity, making companies like CrowdStrike (NASDAQ: CRWD) and SentinelOne (NYSE: S) excellent investment opportunities. But is there an advantage to buying one over the other now? Both companies' base products are AI-powered protection platforms that analyze digital activity and learn to spot the threats among the normal activity. They deploy their software to network endpoints -- in other words, laptops, smartphones, and other devices that can access a client's internal network. By protecting these devices, companies make it harder for cyberattackers to gain access to their internal networks, where they might steal sensitive information, delete files, interfere with systems, or even lock them down with ransomware to extort payments from their victims. While endpoint protection is how both companies land clients, each bolsters its offerings with an array of other cybersecurity products that clients can use to create a protection suite tailored to their unique situations. Since these two direct competitors offer highly similar product types, it's hard to declare either a winner on this front from an investor perspective. Winner: Tie. From a sheer size perspective, CrowdStrike is the clear winner. During its fiscal 2026 first quarter, which ended April 30, CrowdStrike's annual recurring revenue (ARR) rose to $4.4 billion. SentinelOne's ARR of $948 million in its fiscal Q1 was less than a quarter of that. While size doesn't always matter, in this case, it does. Because so many more companies use CrowdStrike's platform, it's more likely that any given IT professional will have at least one contact already on its client list. If CrowdStrike is doing a great job with those clients, word will spread, and it will likely receive more serious consideration in future cybersecurity bidding processes. This advantage cannot be understated. Indeed, it's one of the reasons why CrowdStrike's growth has remained strong despite its size. Winner: CrowdStrike In terms of growth rates, SentinelOne is slightly outperforming CrowdStrike in this category. However, this should be no surprise because SentinelOne is a much smaller company. In fiscal Q1, SentinelOne's ARR rose 24% year over year, while CrowdStrike's increased 22% year over year. While I will give the point to SentinelOne, it's important to understand that CrowdStrike is growing from a much larger base than SentinelOne, making this close call all the more impressive for CrowdStrike. Winner: SentinelOne Due to its smaller size and focus on top-line growth, SentinelOne is far from profitable, while CrowdStrike has achieved intermittent profitability (although it reverted to a negative operating margin and a loss in its most recent quarter). SentinelOne is far from breaking even, but CrowdStrike was in this same position about five years ago. There's no reason not to expect SentinelOne to follow a similar path to profitability, but it will take some time. Meanwhile, CrowdStrike should eventually turn a profit again, as it has proven that it can do that. Winner: CrowdStrike CrowdStrike is leading this battle of the stocks so far, but SentinelOne is about to change the narrative with one jaw-dropping metric. CrowdStrike is the most popular cybersecurity stock in the market, and as a result, it has been bid up to expensive levels. From a price-to-sales (P/S) standpoint (the best metric to use to compare these companies since CrowdStrike flips between profitable and unprofitable, while SentinelOne is years away from profits), CrowdStrike has gotten far more expensive than SentinelOne over the past few years. CrowdStrike stock is now five times more expensive than SentinelOne, which is hard to believe, considering they compete in the same industry and are growing at nearly identical rates. This leads me to believe that CrowdStrike's stock has been overly hyped up while SentinelOne has been forgotten. While I'm OK with valuing CrowdStrike at a premium due to its market leadership position, this is far too great a premium to pay. SentinelOne is a dirt-cheap stock, and CrowdStrike is almost too expensive to consider. While I have been a long-term CrowdStrike bull, I'd be a bit cautious about buying the stock at its current lofty valuation. As a result, I think SentinelOne is the better cybersecurity investment right now. Before you buy stock in CrowdStrike, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CrowdStrike wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Keithen Drury has positions in CrowdStrike. The Motley Fool has positions in and recommends CrowdStrike. The Motley Fool has a disclosure policy. Better Cybersecurity Stock: CrowdStrike or SentinelOne? was originally published by The Motley Fool Sign in to access your portfolio

Business Insider

an hour ago

• Business Insider

3 Economic Events That Could Affect Your Portfolio This Week, June 23-27, 2025

Stocks closed mixed on Friday amid hopes for de-escalation in the Middle East, still clocking in a second straight week in the red. Despite eking out a small increase on the last trading day of the holiday-shortened week, the Dow Jones Industrial Average (DJIA) ended the weekly session down 1.77%, returning to a year-to-date loss. Meanwhile, the S&P 500 (SPX) fell 1.28%, and the tech-heavy Nasdaq-100 (NDX) lost 1.31% for the week, with both benchmarks still in the green for the year. Confident Investing Starts Here: Stock markets were moved by geopolitical news during the week, with the Federal Reserve's policy meeting adding a significant macro highlight. The week opened positively as fears of all-out Mideast war eased, after which the rally crumbled – and crude resumed its climb – as Tehran threatened escalation and former President Donald Trump demanded 'total surrender.' After Thursday's Juneteenth closure, investors returned on Friday hoping for the best – but stocks lost ground throughout the day on another bout of trade news. The declines were led by semiconductor and chip equipment stocks, which fell after The Wall Street Journal reported that the U.S. plans to cancel the blanket waivers that allow international chip companies like Samsung, SK Hynix , and TSMC to easily send American chipmaking equipment to their factories in China. Wednesday's Fed interest rate decision brought no surprises, as the central bank kept rates unchanged, noting that uncertainty 'has diminished but remains elevated.' Fed Chair Jerome Powell noted that 'the economy is in a solid position,' and the Fed is well-positioned to provide a timely response to any economic developments. The Fed's 'Dot Plot' also remained unchanged, as policymakers still expect two rate cuts this year. However, expectations for inflation and unemployment by the end of 2025 both rose, while projections for GDP growth declined, underscoring the Fed's difficulties in establishing monetary policy amid contrasting economic crosscurrents and elevated geopolitical risks. Meanwhile, economic data appear to be confirming the Fed's view of a gradually softening economy. Retail sales fell for a second straight month in May, declining by the most so far in 2025 and marking the first back-to-back monthly decline since the end of 2023. Industrial production declined again, and the NAHB homebuilder confidence index slumped to its lowest since the end of 2022 – while new home construction dropped to the lowest level since 2020. This and other data, coupled with the Fed's updated economic projections, might keep 'stagflation' in the headlines. Sunday's news that the U.S. had struck Iran's nuclear facilities set the stage for a further rise in oil prices, adding short-term inflationary pressures and weighing on investor risk appetite. Markets remain wedged between escalating global risk and weakening fundamentals – with Fed policy constrained, volatility high, and few near-term catalysts to shift sentiment decisively. Three Economic Events Here are three key economic events that could affect your portfolio this week. For a full listing of additional economic reports, check out the TipRanks Economic Calendar. » June's S&P Global Manufacturing PMI and Services PMI (preliminary readings) – Monday, 06/23 – PMI indices are leading economic indicators used by economists and analysts to gain timely insights into changing economic conditions, as the direction and rate of change in the PMIs usually precede changes in the overall economy. » May's Core Personal Consumption Expenditures (Core PCE) – Friday, 06/27 – This report tracks changes in inflation based on consumer spending, excluding volatile items such as food and energy. The Federal Reserve considers the annualized Core PCE Price Index its preferred inflation gauge. » June's Michigan Consumer Sentiment Index and UoM 5-year Consumer Inflation Expectations (preliminary readings) – Friday, 06/27 – These reports summarize consumer confidence and long-term inflation expectations in the U.S. Consumer confidence impacts spending, which accounts for roughly 70% of U.S. GDP. The inflation expectations component is closely monitored by policymakers and is factored into the Federal Reserve's Index of Inflation Expectations.